Genzyme Corp. met its primary and secondary endpoints in a second Phase III trial of Mozobil in multiple myeloma (MM) similar to the recent trial in non-Hodgkin’s lymphoma. The combined results of these two trials—in which patients with two types of cancer achieved more rapid and effective mobilization of stem cells in preparation for transplant than patients treated with current therapies—will support the drug’s regulatory approval. The randomized, double-blind, placebo-contro...